Delayed administration of dexrazoxane provides cordiaprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1333-1340

  Swain, S M ^a   Whaley, F S ^a   Gerber, M C ^a   Ewer, M S ^a   Bianchine, J R ^a   Gams, R A ^a  

^a Comprehensive Breast Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PLACEBO; PROGESTERONE RECEPTOR; RAZOXANE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TUMOR GROWTH;

EID: 0030991044     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1333     Document Type: Article

References (10)

1. Creighton AM, Hellmann K, Whitecross S: Antitumor activity in a series of bisdiketopiperazines. Nature 222:384-385, 1969
2. Koeller JM, Earhart RH, Davis HL: Phase 1 trial of ICRF-187 by 48-hour continuous infusion. Cancer Treat Rep 65:459-463, 1981
3. Liesmann J, Belt R, Haas C, et al: Phase 1 evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy. Cancer 47:1959-1962, 1981
4. Von Hoff DD, Howser D, Lewis BJ, et al: Phase 1 study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249-252, 1981
5. Herman EH, Mhatre RM, Lee IP, et al: Prevention of the cardiotoxic effects of Adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med 140:234-239, 1972
6. Herman EH, Ferrans VJ, Jordan W, et al: Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31:85-97, 1981
7. Verhoef V, Colborn D, Stark R, et al: Effect of ADR-529 (ICRF-187) on the development of delayed doxorubicin cardiotoxicity in the Bertazzoli mouse model. Dublin, OH, Adria Labs Internal Report no. PLS 90-5 and P-529-86-003. September 20, 1991, p 104
8. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
9. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
10. Schwartz RG, McKenzie WD, Alexander J, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angio-cardiography. Am J Med 82:1109-1118, 1987